NT-I7 (efineptakin alfa), un IL-7 umano a lunga durata di lunga durata, post-yescarta® (axicabtagene ciloleucel) o post-Breyanzi® (Lisocabtagene MaraleuCel) in soggetti con linfoma a grandi dimensioni malato/refrattario
Uno studio di fase 1b che valuta la sicurezza, la tollerabilità e l'attività antitumorale preliminare di NT-I7 (efineptakin alfa), un IL-7 umano ad azione prolungata, post-yescarta® (ciloucel a base di ranautica) o relumoufoma) o relumfoma)
Diffuse large B-cell lymphoma is the most commonly occurring subtype of non-Hodgkin lymphoma, but treatment is often not curative, with as many as 50% of patients with adverse risk factors developing relapsed/refractory disease. CAR T-cell therapy has revolutionized modern cancer therapy, with axicabtagene ciloleucel and lisocabtagene maraleucel (anti-CD19 CAR T-cell therapies) FDA approved for second- or later-line treatment of relapsed/refractory large B-cell lymphoma.
IL-7 plays a crucial role in T-cell homeostasis by inducing thymic differentiation, peripheral expansion, and extrathymic differentiation. It is the main regulator of T-cell hemostasis, inducing T-cell growth and proliferation in lymphopenic patients. There is data that suggests that exposure of T-cells to IL-7 may expand T-cells, prevent T-cell exhaustion, and improve effector functions.
NT-I7 is a long-acting human IL-7 cytokine which has been shown in nonclinical studies to increase peripheral T-cells, antitumor efficacy, and tumor infiltrating lymphocytes, either as a monotherapy or in combination with chemo/radiotherapy and/or immune checkpoint inhibitors and CAR T therapy.
This study is testing the hypothesis that the administration of NT-I7 following standard of care (SOC) approved CD19 CAR T-cell therapies for subjects with relapsed/refractory large B-cell lymphoma (LBCL) will be safe and tolerable and may increase the expansion and persistence of CAR T-cells in vivo, which may result in increased tumor response rate and improved clinical outcomes.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Zachary D Crees, M.D.
- Numero di telefono: 314-273-1039
- Email: zcrees@wustl.edu
Luoghi di studio
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University School of Medicine
-
Sub-investigatore:
- John F DiPersio, M.D., Ph.D.
-
Sub-investigatore:
- Feng Gao, Ph.D.
-
Contatto:
- Zachary D Crees, M.D.
- Numero di telefono: 314-273-1039
- Email: zcrees@wustl.edu
-
Investigatore principale:
- Zachary D Crees, M.D.
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Histologically confirmed relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, DLBCL arising from an indolent lymphoma, grade 3B follicular lymphoma and primary mediastinal large B-cell lymphoma.
-
Measurable disease by IWG response criteria for lymphoma.
- Baseline FDG-PET/CT scan must show FDG-avid lesions compatible with CT-defined anatomical tumor sites.
- A previously irradiated lesion can be considered a target lesion if it is well defined, measurable, and has clearly progressed following radiation.
- FDG-PET/CT scans done as SOC up to 60 days pre-lymphodepletion therapy will be allowed. NOTE: After eligibility is confirmed, restaging FDG-PET/CT scans will not be used to change eligibility.
-
Eligible for treatment with an FDA-approved SOC CD19 CAR T-cell therapy respective to the current FDA-approved CAR T-cell label for axi-cel(Yescarta®) or liso-cel (Breyanzi®).
-
If the patient has previously received an autologous stem cell transplant, s/he must be at least 3 months post-transplant.
-
At least 18 years of age.
-
ECOG performance status ≤ 2
-
Adequate bone marrow and organ function at the start of lymphodepleting chemotherapy as pre-conditioning for SOC CD19 CAR T-cell infusion as defined below:
- Absolute neutrophil count ≥ 1.0 K/cumm
- Platelets ≥ 50 K/cumm
- Hemoglobin ≥ 8.0 g/dL
- Total bilirubin ≤ 1.5 x IULN or direct bilirubin ≤ IULN for patients with total bilirubin levels > 1.5 x IULN (except for patients with Gilbert's syndrome, who must have a baseline total bilirubin ≤ 3.0 mg/dL)
- AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN (except for patients with documented liver involvement or bone metastases, who must have an AST and/or ALT ≤ 5.0 x IULN)
- Alkaline phosphatase ≤ 2.5 x IULN (except for patients with liver metastasis, who must have an alkaline phosphatase ≤ 5.0 x IULN)
- Creatinine clearance ≥ 30 mL/min by Cockcroft-Gault
- INR and aPTT ≤ 1.5 x IULN unless the patient is receiving anticoagulant therapy and the PT or aPTT is within the therapeutic range for the anticoagulant. Patients who are on anticoagulation should be able to hold the anticoagulant for 4-5 half-lives of the anticoagulant prior to IM NT-I7 injection to reduce risk of hematoma.
-
ECG demonstrating Fridericia's corrected QT interval (QTcF) < 500 ms; patients with QTcF ≥ 500 ms will require clearance by a cardiologist.
-
The effects of NT-I7 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days after the last NT-I7 injection. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s/he must inform her treating physician immediately.
-
Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.
Exclusion Criteria:
-
Previous receipt of an allogeneic solid organ transplant or bone marrow transplant.
-
Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
-
Chemotherapy or biologic or hormonal therapy for prior or concurrent cancer treatment, within 14 days prior to the first NT-I7 injection.
- NOTE: Concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes, hormone replacement therapy) is acceptable.
-
Currently receiving any other investigational agents, or received within 14 days prior to the first NT-I7 injection.
-
Documented active central nervous system (CNS) involvement by lymphoma.
-
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to NT-I7 or other agents used in the study.
-
Presence of clinically significant, unresolved toxicities from prior anticancer therapy, defined as having not received to grade ≤ 1 (with the exception of alopecia and laboratory values listed per the inclusion criteria). Patients with irreversible toxicity that is not reasonably expected to be exacerbated by NT-I7 may be included (e.g., hearing loss, peripheral neuropathy) after consultation with the PI.
-
Uncontrolled intercurrent illness including, but not limited to:
-
Ongoing or active infection (including active hepatitis A or mycobacterium tuberculosis (testing not required))
-
Congestive heart failure with NYHA Class ≥ 2
-
Uncontrolled atrial fibrillation
-
Any of the following within 6 months prior to day of CAR T-cell administration:
- Unstable angina pectoris
- Myocardial infarction
- Coronary artery bypass grafting
- Coronary angioplasty
- Coronary stenting
- Clinically significant cardiac arrhythmia and/or conduction abnormality
-
Other clinically significant cardiac disease that, in the opinion of the treating physician and/or PI, is a contraindication to study treatment
-
-
History of autoimmune disease for the past 2 years prior to enrollment, including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
- NOTE: The following are exceptions to this criterion: vitiligo, alopecia, type 1 diabetes mellitus, autoimmune hypothyroidism stable on hormone replacement, psoriasis not severe enough to require systemic treatment, diverticulitis not associated with inflammatory bowel disease.
-
Contraindication to intramuscular therapy.
-
Receipt of a live, attenuated vaccine within 30 days prior to NT-I7 injection.
- NOTE: Patients, if enrolled, should not receive live vaccines during the study period and through 30 days after the last NT-I7 injection. The administration of inactivated vaccines is permitted at any time per the discretion of the treating physician.
-
Pregnant and/or breastfeeding and/or expecting to conceive or father children within the study duration (from enrollment through 90 days after last dose of NT-I7). Women of childbearing potential (including women who have had a tubal ligation) must have a negative serum or urine pregnancy test within 72 hours prior to CAR-T administration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
-
HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible.
-
Evidence of chronic hepatitis B virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible.
-
History of hepatitis C virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
|---|
|
Sperimentale: Dose Escalation Dose Level 1 Starting Dose: NT-I7
NT-I7 will be administered as an intramuscular injection at 600 μg/kg on Day 10 (-2/+5 days) and Day 31 (+/-3 days) post-CAR T-cell therapy infusion, with at least 2 weeks between the NT-I7 injections. |
|
Sperimentale: Dose Escalation Dose Level 2: NT-I7
NT-I7 will be administered as an intramuscular injection at 720 μg/kg on Day 10 (-2/+5 days) and Day 31 (+/-3 days) post-CAR T-cell therapy infusion, with at least 2 weeks between the NT-I7 injections. |
|
Sperimentale: Dose Expansion (RP2D): NT-I7
NT-I7 will be administered as an intramuscular injection at the recommended phase 2 dose on Day 10 (-2/+5 days) and Day 31 (+/-3 days) post-CAR T-cell therapy infusion, with at least 2 weeks between the NT-I7 injections. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of adverse events
Lasso di tempo: From start of CAR T-cell infusion (day 0) through day 90 (post CAR T-cell infusion)
|
Measured per CTCAE v 5.0. CRS and ICANS will be graded per ASTCT guidelines |
From start of CAR T-cell infusion (day 0) through day 90 (post CAR T-cell infusion)
|
|
Maximum tolerated dose of NT-I7 (Dose Escalation only)
Lasso di tempo: From first dose of NT-I7 until 14 days after the second dose NT-I7 dose (estimated to be 35 days)
|
Determined by incidence and nature of dose-limiting toxicities (DLTs). DLTs are defined in the protocol. |
From first dose of NT-I7 until 14 days after the second dose NT-I7 dose (estimated to be 35 days)
|
|
Recommended phase 2 dose of NT-I7 (Dose Escalation only)
Lasso di tempo: Through 90 days after CAR T-cell infusion
|
Determined by the potential correlation of dose levels with safety and efficacy parameters. |
Through 90 days after CAR T-cell infusion
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Effetto di NT-I7 sull'espansione delle cellule T CAR misurato mediante PCR quantitativa del DNA e/o citometria a flusso
Lasso di tempo: Dal giorno 0 al giorno 42 dopo l'infusione di cellule T CAR
|
Dal giorno 0 al giorno 42 dopo l'infusione di cellule T CAR
|
|
|
Overall response rate (ORR)
Lasso di tempo: Through completion of follow-up (estimated to be 1 year)
|
Response will be assessed based on IWG response criteria for lymphoma |
Through completion of follow-up (estimated to be 1 year)
|
|
Partial response (PR) rate
Lasso di tempo: Through completion of follow-up (estimated to be 1 year)
|
Response will be assessed based on IWG response criteria for lymphoma |
Through completion of follow-up (estimated to be 1 year)
|
|
Complete response (CR) rate
Lasso di tempo: Through completion of follow-up (estimated to be 1 year)
|
Response will be assessed based on IWG response criteria for lymphoma |
Through completion of follow-up (estimated to be 1 year)
|
|
Duration of response (DoR)
Lasso di tempo: Through completion of follow-up (estimated to be 1 year)
|
For responders only: defined as the time from the first occurrence of a documented objective response (PR or CR) to the time of the first documented disease progression or death from any cause, whichever occurs first, per IWG. Response will be assessed based on IWG response criteria for lymphoma |
Through completion of follow-up (estimated to be 1 year)
|
|
Progression-free survival (PFS)
Lasso di tempo: Through completion of follow-up (estimated to be 1 year)
|
Defined as the time from the CAR T-cell infusion (Day 0) to the first occurrence of progression or death from any cause, whichever occurs first, per IWG. |
Through completion of follow-up (estimated to be 1 year)
|
|
Overall survival (OS)
Lasso di tempo: Through completion of follow-up (estimated to be 1 year)
|
Defined as the time from CAR T-cell infusion (Day 0) to death from any cause. |
Through completion of follow-up (estimated to be 1 year)
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Zachary D Crees, M.D., Washington University School of Medicine
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma
- Malattie emiche e linfatiche
- Linfoma non Hodgkin
- Tecniche investigative
- Terapie
- Terapia biologica
- Tecniche immunologiche
- Immunomodulazione
- Trasferimento adottivo
- Immunizzazione, passivo
- Immunizzazione
- Immunoterapia
- Axicabtagene Ciloleucel
- efineptakin alfa
- Immunoterapia, adottiva
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 202512084
- R01CA286488 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .